[{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"TherapeuticsMD","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ TherapeuticsMD"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Peking Union Medical College Hospital \/ Merck Group"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Merck Group \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Merck & Co"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor||Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Patch","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SIFI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"SIFI \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SIFI \/ Undisclosed"},{"orgOrder":0,"company":"SIFI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"SIFI \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SIFI \/ Undisclosed"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"MedinCell","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Hormone","year":"2022","type":"Funding","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"MedinCell","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Andromaco","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Pessary","sponsorNew":"Grunenthal \/ Andromaco","highestDevelopmentStatusID":"8","companyTruncated":"Grunenthal \/ Andromaco"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FARMAK, a.s \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"FARMAK, a.s \/ Undisclosed"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FARMAK, a.s \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"FARMAK, a.s \/ Undisclosed"},{"orgOrder":0,"company":"Geha Mental Health Center","sponsor":"Samsung Medical Center | Han Wha Pharma | Ministry of Health & Welfare, Korea","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"ISRAEL","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Geha Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geha Mental Health Center \/ Samsung Medical Center | Han Wha Pharma | Ministry of Health & Welfare, Korea","highestDevelopmentStatusID":"10","companyTruncated":"Geha Mental Health Center \/ Samsung Medical Center | Han Wha Pharma | Ministry of Health & Welfare, Korea"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Obstetrix Medical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Obstetrix Medical Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Obstetrix Medical Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Obstetrix Medical Group \/ Undisclosed"},{"orgOrder":0,"company":"Fertility Centers of Illinois","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Fertility Centers of Illinois","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fertility Centers of Illinois \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Fertility Centers of Illinois \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Clinique Ovo","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Clinique Ovo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clinique Ovo \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Clinique Ovo \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Shady Grove Fertility","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Shady Grove Fertility","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shady Grove Fertility \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Shady Grove Fertility \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Productos Cientificos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"MEXICO","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Productos Cientificos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Productos Cientificos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Productos Cientificos \/ Undisclosed"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Juniper Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Rochester \/ Juniper Pharmaceuticals, Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Rochester \/ Juniper Pharmaceuticals, Inc"},{"orgOrder":0,"company":"Eastern Virginia Medical School","sponsor":"Watson Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Eastern Virginia Medical School","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Eastern Virginia Medical School \/ Watson Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Eastern Virginia Medical School \/ Watson Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer CentreOne","sponsor":"Effik","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Pfizer CentreOne","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer CentreOne \/ Effik","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer CentreOne \/ Effik"},{"orgOrder":0,"company":"Signal 12","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Signal 12","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Signal 12 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Signal 12 \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dar\u00e9 Bioscience \/ Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ Gansu Provincial Maternal and Child Health Care Hospital"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TherapeuticsMD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TherapeuticsMD \/ Undisclosed"},{"orgOrder":0,"company":"Reproductive Health Research Insritute, Chile","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHILE","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Reproductive Health Research Insritute, Chile","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reproductive Health Research Insritute, Chile \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Reproductive Health Research Insritute, Chile \/ Undisclosed"},{"orgOrder":0,"company":"BHR Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"BHR Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BHR Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BHR Pharma \/ Undisclosed"},{"orgOrder":0,"company":"EVE Medical Systems","sponsor":"Semmelweis University","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"EVE Medical Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EVE Medical Systems \/ Semmelweis University","highestDevelopmentStatusID":"8","companyTruncated":"EVE Medical Systems \/ Semmelweis University"},{"orgOrder":0,"company":"BHR Pharma","sponsor":"PRA Health Sciences | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BHR Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BHR Pharma \/ PRA Health Sciences | Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"BHR Pharma \/ PRA Health Sciences | Syneos Health"},{"orgOrder":0,"company":"Sara Ghandehari","sponsor":"IBSA Institut Biochimique","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sara Ghandehari","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sara Ghandehari \/ IBSA Institut Biochimique","highestDevelopmentStatusID":"6","companyTruncated":"Sara Ghandehari \/ IBSA Institut Biochimique"},{"orgOrder":0,"company":"Calla Lily Clinical Care Ltd","sponsor":"University Hospitals Coventry and Warwickshire NHS Trust | University of Warwick","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Calla Lily Clinical Care Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calla Lily Clinical Care Ltd \/ University Hospitals Coventry and Warwickshire NHS Trust | University of Warwick","highestDevelopmentStatusID":"6","companyTruncated":"Calla Lily Clinical Care Ltd \/ University Hospitals Coventry and Warwickshire NHS Trust | University of Warwick"}]
Find Clinical Drug Pipeline Developments & Deals for Progesterone
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target